Key Points
- Denali Therapeutics insider Alexander Schuth sold 2,857 shares at an average price of $25.07, totaling approximately $71,625. He retains 281,763 shares valued at about $7.06 million.
- DNLI shares opened at $24.82 after declining 1.8%; the company reported a quarterly loss of $0.68 per share, missing estimates, though revenue of $3.6 million exceeded expectations.
- Analysts maintain a “Moderate Buy” consensus rating with an average price target of $35.92, while institutional investors own 92.92% of the company.
Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Alexander Schuth sold 2,857 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Denali Therapeutics Trading Down 1.8%
Shares of DNLI stock opened at $24.82 on Friday. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.97 billion, a P/E ratio of -8.74 and a beta of 1.01. The company has a 50 day moving average of $23.94 and a 200-day moving average of $21.46. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $27.30.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same quarter last year, the firm posted ($0.72) EPS. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.6 earnings per share for the current year.
Hedge Funds Weigh In On Denali Therapeutics
Large investors have recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Denali Therapeutics during the second quarter valued at approximately $26,000. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the 2nd quarter worth approximately $26,000. Global Retirement Partners LLC purchased a new stake in Denali Therapeutics in the 2nd quarter worth approximately $28,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics in the 3rd quarter worth approximately $29,000. Finally, State of Wyoming bought a new position in Denali Therapeutics in the 2nd quarter valued at $29,000. 92.92% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several brokerages recently weighed in on DNLI. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a report on Monday, July 13th. They issued an "overweight" rating and a $29.00 price objective for the company. BTIG Research reiterated a "buy" rating and set a $39.00 target price on shares of Denali Therapeutics in a research report on Monday, May 11th. Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a research note on Friday, August 7th. Leerink Partners lowered their price target on shares of Denali Therapeutics from $40.00 to $35.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 22nd. Finally, Stifel Nicolaus set a $41.00 price target on shares of Denali Therapeutics in a research note on Monday, June 22nd. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.92.
View Our Latest Report on DNLI
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
